iBio, Inc. Form 10-Q Summary
Business context and reporting period
iBio is a biotechnology company commercializing the iBioLaunch platform for vaccines and therapeutic proteins and the iBioModulator platform for vaccine enhancement. Its strategy depends on licensing, collaboration, and development arrangements. The filing covers the three and six months ended December 31, 2012, representing the second quarter and first six months of fiscal 2013. The financial statements are unaudited.
Key financial metrics
| Metric | Three months ended Dec. 31, 2012 | Three months ended Dec. 31, 2011 | Six months ended Dec. 31, 2012 | Six months ended Dec. 31, 2011 |
|---|---|---|---|---|
| Revenue | $0 | $233,832 | $390,186 | $554,180 |
| Operating loss | $(1,695,171) | $(2,673,644) | $(3,505,189) | $(4,998,670) |
| Net loss | $(1,071,154) | $(1,597,660) | $(3,122,581) | $(1,214,517) |
| Net loss per share | $(0.02) | $(0.05) | $(0.07) | $(0.04) |
| Operating cash flow | Not separately provided | Not separately provided | $(2,693,774) | $(2,012,438) |
Revenue consisted primarily of technology services related to the Fiocruz yellow fever vaccine collaboration. No revenue was recognized in the December 2012 quarter while iBio, Fiocruz, and FhCMB negotiated modifications to the work plan.
| Balance-sheet item | Dec. 31, 2012 | June 30, 2012 |
|---|---|---|
| Cash | $2,818,964 | $5,624,403 |
| Total current assets | $3,995,235 | $6,900,145 |
| Total assets | $6,805,157 | $9,764,582 |
| Total liabilities | $3,088,300 | $3,595,543 |
| Stockholders’ equity | $3,716,857 | $6,169,039 |
| Accumulated deficit | $(34,460,362) | $(31,337,781) |
The filing does not report conventional long-term debt. Current liabilities included $2.71 million of accounts payable, $251,481 of accrued expenses, and a $125,500 derivative financial liability. The derivative liability declined from $519,725 at June 30, 2012 and generated $394,225 of non-cash income during the six-month period.
Material changes versus the prior comparable period
- Six-month revenue declined 30% to $390,186 from $554,180; quarterly revenue declined to zero from $233,832 because Fiocruz work-plan negotiations delayed revenue recognition.
- Six-month operating expenses declined 30% to $3.90 million from $5.55 million. Research and development expense fell to $1.83 million from $2.62 million, primarily because certain FhCMB projects ended or were reduced.
- General and administrative expense declined to $2.06 million from $2.93 million, mainly due to lower stock-based compensation and the absence of certain prior-period option-modification and warrant charges.
- Despite lower operating expenses, six-month net loss increased to $3.12 million from $1.21 million because prior-year results benefited from $3.79 million of non-cash derivative income, compared with $394,225 in the current period.
- Cash declined by $2.81 million from June 30, 2012, primarily due to operating cash use. Stockholders’ equity decreased by $2.45 million.
- Stock-based compensation was $670,399 for the six months ended December 31, 2012. The company had 6.66 million options and 21.04 million warrants outstanding, creating substantial potential dilution.
Outlook, liquidity, risks, and unusual items
- Management estimated that cash on hand at December 31, 2012 would fund operations through the end of the second calendar quarter of 2013. The filing states that recurring losses, negative operating cash flow, and limited cash resources raise substantial doubt about the company’s ability to continue as a going concern.
- On January 31, 2013, iBio entered into an at-the-market equity offering allowing sales of up to $10 million of common stock. No sales had occurred under the ATM as of the filing. Proceeds, if available, are intended for technology development, business development, and general corporate purposes. The filing notes that Form S-3 limitations could reduce the amount raised; at February 12, 2013, the estimated available amount was approximately $8.62 million.
- Additional financing may dilute existing shareholders. If financing is unavailable, iBio may delay or discontinue development, accept less favorable collaborations, relinquish rights, or cease operations.
- The NYSE MKT accepted iBio’s compliance plan and granted an extension to October 14, 2013 to regain compliance with the requirement related to stockholders’ equity below $6 million and losses in the five most recent years. The company anticipated a possible additional non-compliance notice concerning the $4 million equity standard.
- On February 14, 2013, iBio entered into a license and collaboration agreement with Caliber Biotherapeutics. Potential consideration includes license and milestone fees and future royalties, but the filing does not provide guaranteed amounts or timing.
- Amounts owed to FhCMB represented approximately 89% of accounts payable at December 31, 2012. The parties were negotiating an amendment to focus future research on designated product-specific work.
- The August 2008 warrant derivative liability is subject to significant mark-to-market volatility and anti-dilution provisions and is expected to affect earnings until the warrants expire in August 2013 or are exercised.
- Key business risks include dependence on collaborators, regulatory and clinical approval, technology development, intellectual-property protection, competition, market acceptance, key personnel, and the ability to generate license or product revenues.
Investor verification checklist
- Verify subsequent ATM sales, net proceeds, share issuance, and resulting dilution.
- Assess cash burn and whether financing was obtained before the projected second-calendar-quarter 2013 cash runway expired.
- Review subsequent developments concerning NYSE MKT compliance and continued listing.
- Confirm whether the Fiocruz work-plan amendment was completed and whether related service revenue resumed.
- Evaluate the commercial progress, milestones, funding obligations, and royalty terms under the Caliber collaboration.
- Review FhCMB commitments, related-party transactions, accounts payable concentration, and any amendments to the Technology Transfer Agreement.
- Separate recurring operating performance from non-cash derivative valuation gains and stock-based compensation effects.